Department of Gastroenterology and Hepatology, St George Hospital, Kogarah, New South Wales, Australia.
Intern Med J. 2010 Apr;40(4):258-64. doi: 10.1111/j.1445-5994.2010.02163.x. Epub 2010 Jan 4.
Our understanding of inflammatory bowel diseases (IBD) is constantly evolving, and many new treatment options have emerged recently. This review critically examines the evidence for these new developments and aims to provide an overview for medical professionals involved in the care of patients with IBD. Proposed changes in the use of aminosalicylates, immunosuppressants and biological agents are described, and the evidence for several promising novel agents is reviewed.
我们对炎症性肠病(IBD)的认识在不断发展,最近出现了许多新的治疗选择。本综述批判性地评估了这些新进展的证据,并旨在为参与 IBD 患者治疗的医疗专业人员提供概述。描述了氨基水杨酸盐、免疫抑制剂和生物制剂使用的拟议改变,并回顾了几种有前途的新型药物的证据。